Efficacy of Losartan in Preventing Progression of COPD

COPD Clinical Trial

Official title: Efficacy of Losartan in Preventing Progression of COPD

Status Active, not recruiting

Clinical Trial Summary

Evidence in animals shows that losartan can prevent or reverse inflammation and lung damage due to smoking. The goal of this study is to determine whether this drug which is also used to treat hypertension can stabilize or improve lung function in people who have from chronic obstructive pulmonary disease (COPD).

Clinical Trial Description

Participants will be given either losartan in a dose of 50-100 mg per day for a period of one year. During that time, they will have lung function tests, breathing tests, and computed tomograms of the chest. These tests will determine whether there is inflammation in the lung and whether there is progressive involvement of the lung with COPD. ;

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Bronchitis
• Bronchitis, Chronic
• Chronic Bronchitis
• COPD
• Emphysema
• Smoking

• NCT number: NCT00720226
• Study type: Interventional
• Source: Johns Hopkins University
• Status: Active, not recruiting
• Phase: Phase 4
• Start date: July 2008
• Completion date: August 2013